| Literature DB >> 34343484 |
Alejandro Méndez-Mancilla1, Hans-Hermann Wessels1, Mateusz Legut1, Anastasia Kadina2, Megumu Mabuchi3, John Walker2, G Brett Robb3, Kevin Holden2, Neville E Sanjana4.
Abstract
RNA-targeting CRISPR-Cas13 proteins have recently emerged as a powerful platform to modulate gene expression outcomes. However, protein and CRISPR RNA (crRNA) delivery in human cells can be challenging with rapid crRNA degradation yielding transient knockdown. Here we compare several chemical RNA modifications at different positions to identify synthetic crRNAs that improve RNA targeting efficiency and half-life in human cells. We show that co-delivery of modified crRNAs and recombinant Cas13 enzyme in ribonucleoprotein (RNP) complexes can alter gene expression in primary CD4+ and CD8+ T cells. This system represents a robust and efficient method to modulate transcripts without genetic manipulation.Entities:
Keywords: CRISPR type-VI; cas13; chemical modifications; transcriptome regulation
Mesh:
Substances:
Year: 2021 PMID: 34343484 PMCID: PMC8792099 DOI: 10.1016/j.chembiol.2021.07.011
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116